OBJECTIVE Choices of pharmacologic therapies for pulmonary arterial hypertension (PAH)
are ideally guided by high-level evidence. The objective of this guideline is to provide …

Background Pulmonary arterial hypertension (PAH) carries a poor prognosis if not promptly
diagnosed and appropriately treated. The development and approval of 14 medications over …

Pulmonary arterial hypertension (PAH) is a life-threatening and progressive disease of
various origins characterized by pulmonary vascular remodeling that leads to increased …

Lee SH, Rubin LJ (University of California, San Diego, La Jolla, CA, USA). Current treatment
strategies for pulmonary arterial hypertension (Review). J Intern Med 2005; 258: 199–215 …

A consensus panel convened by the American College of Chest Physicians developed
guidelines for the treatment of pulmonary arterial hypertension (PAH) that were published in …

Background Previous meta-analyses of treatments for pulmonary arterial hypertension
(PAH) have not shown mortality benefit from any individual class of medication. Methods …

Pulmonary arterial hypertension (PAH) is often difficult to diagnose and challenging to treat.
Untreated, it is characterized by a progressive increase in pulmonary vascular resistance …

Background: Pulmonary arterial hypertension (PAH) is a debilitating chronic disorder of the
pulmonary vasculature characterized by elevated mean pulmonary arterial pressure, right …

Uncontrolled and controlled clinical trials with different compounds and procedures are
reviewed to define the risk-benefit profiles for therapeutic options in pulmonary arterial …

The numerous controlled clinical trials performed recently in pulmonary arterial hypertension
(PAH) can allow us to abandon a clinical-based treatment strategy and adopt an evidence …